Amit Patel, BSc, MBBS, PhD, reviews key takeaways from the 2021 European Society for Blood and Marrow Transplantation symposium regarding the use of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 1: Unmet Needs in Relapsed/Refractory DLBCL
An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.
EP. 2: Options for CAR-T Therapy in the Third-Line Setting
A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.
EP. 3: Best Practices for Early Referral and Bridging Therapy
Amit Patel, BSc, MBBS, PhD, discusses best practices for referring patients to CAR T centers earlier and provides advice on bridging therapy to debulk disease burden at the time of CAR T-cell therapy.
EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy
A key opinion leader in hematology and oncology shares insights on factors to consider for optimal patient selection and treatment sequencing, such as thresholds for tolerability, renal function, and cardiac ejection fraction.
EP. 5: Research on CAR T Therapy in Earlier Lines of Treatment
Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer
Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer
Mahtani Emphasizes Empowering Women in Oncology Through Sponsorship, Support Networks, and Self Care
McCann on the Intersection of Mentorship, Multidisciplinary Care, and Career Aspirations as a Woman in Oncology